Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis [4]

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2656-2657

  Freifeld, Alison ^a   Arnold, Sandra ^b   Ooi, Winnie ^c   Chen, Fabian ^d   Meyer, Thomas ^e   Wheat, L Joseph ^f   Smedema, Melinda ^f   Lemonte, Ann ^f   Connolly, Patricia ^f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^e Clarian Arnett Health   (United States)

^f MIRAVISTA DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

DRUG BLOOD LEVEL; DRUG MONITORING; FUNGUS ISOLATION; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; COHORT STUDIES; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; RECURRENCE; TRIAZOLES;

EID: 34447285720     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01583-06     Document Type: Letter

References (10)

1. Connolly, P., J. Wheat, C. Schnizlein-Bick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Bridendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43:322-328.
2. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
3. Freifeld, A. G., P. C. Iwen, B. L. Lesiak, R. K. Gilroy, R. B. Stevens, and A. C. Kalil. 2005. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl. Infect. Dis. 7:109-115.
4. Lazarus, H. M.. J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
5. Leveque, D., Y. Nivoix, F. Jehl, and R. Herbrecht. 2006. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents 27:274-284.
6. Pascual, A. A., S. Bolay, and O. Marchetti. 2006. Documentation of low voriconazole blood levels followed by dose adjustment in patients with invasive fungal infections not responding to therapy, abstr. M-1304. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006.
7. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1):10-16.
8. Purkins, L., N. Wood, K. Greenhalgh, M. D. Eve, S. D. Oliver, and D. Nichols. 2003. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl. 1):2-9.
9. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
10. Trifilio, S., R. Ortiz, G. Pennick, A. Verma, J. Pi, V. Stosor, T. Zembower, and J. Mehta. 2005. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35:509-513.